PL2121751T3 - Przeciwciała monoklonalne przeciwko ANGPTL3 - Google Patents

Przeciwciała monoklonalne przeciwko ANGPTL3

Info

Publication number
PL2121751T3
PL2121751T3 PL07862629T PL07862629T PL2121751T3 PL 2121751 T3 PL2121751 T3 PL 2121751T3 PL 07862629 T PL07862629 T PL 07862629T PL 07862629 T PL07862629 T PL 07862629T PL 2121751 T3 PL2121751 T3 PL 2121751T3
Authority
PL
Poland
Prior art keywords
monoclonal antibodies
antibodies against
against angptl3
angptl3
monoclonal
Prior art date
Application number
PL07862629T
Other languages
English (en)
Polish (pl)
Inventor
E-Chiang Lee
Gregory Landes
Seokjoo Hong
Urvi Desai
David Powell
Xiao Feng
Original Assignee
Lexicon Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals, Inc. filed Critical Lexicon Pharmaceuticals, Inc.
Publication of PL2121751T3 publication Critical patent/PL2121751T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL07862629T 2006-12-08 2007-12-06 Przeciwciała monoklonalne przeciwko ANGPTL3 PL2121751T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87383406P 2006-12-08 2006-12-08
EP07862629.8A EP2121751B1 (en) 2006-12-08 2007-12-06 Monoclonal antibodies against angptl3

Publications (1)

Publication Number Publication Date
PL2121751T3 true PL2121751T3 (pl) 2017-07-31

Family

ID=39512267

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07862629T PL2121751T3 (pl) 2006-12-08 2007-12-06 Przeciwciała monoklonalne przeciwko ANGPTL3

Country Status (21)

Country Link
US (2) US7935796B2 (cg-RX-API-DMAC7.html)
EP (1) EP2121751B1 (cg-RX-API-DMAC7.html)
JP (1) JP5484063B2 (cg-RX-API-DMAC7.html)
KR (1) KR101503937B1 (cg-RX-API-DMAC7.html)
CN (1) CN101855241B (cg-RX-API-DMAC7.html)
AR (1) AR064205A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007332855B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0720218A2 (cg-RX-API-DMAC7.html)
CA (1) CA2672049C (cg-RX-API-DMAC7.html)
DK (1) DK2121751T3 (cg-RX-API-DMAC7.html)
EA (1) EA019661B1 (cg-RX-API-DMAC7.html)
ES (1) ES2618830T3 (cg-RX-API-DMAC7.html)
HU (1) HUE033960T2 (cg-RX-API-DMAC7.html)
IL (1) IL199216A (cg-RX-API-DMAC7.html)
MX (1) MX2009006082A (cg-RX-API-DMAC7.html)
NO (1) NO20092215L (cg-RX-API-DMAC7.html)
PL (1) PL2121751T3 (cg-RX-API-DMAC7.html)
PT (1) PT2121751T (cg-RX-API-DMAC7.html)
TW (1) TW200846364A (cg-RX-API-DMAC7.html)
WO (1) WO2008073300A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200904022B (cg-RX-API-DMAC7.html)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101503937B1 (ko) * 2006-12-08 2015-03-18 렉시컨 파마슈티컬스 인코퍼레이티드 Ａｎｇｐｔｌ３ 에 대한 단일클론 항체
US9388414B2 (en) 2008-10-08 2016-07-12 Trustees Of Dartmouth College Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases
WO2010042292A1 (en) * 2008-10-08 2010-04-15 Trustees Of Dartmouth College Method for selectively inhibiting the activity of acat1 in the treatment of alzheimer's disease
US9388413B2 (en) 2008-10-08 2016-07-12 Trustees Of Dartmouth College Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases
US8802646B2 (en) 2008-10-08 2014-08-12 Trustees Of Dartmouth College Method for selectively inhibiting the activity of ACAT1 in the treatment of alzheimer's disease
US9149492B2 (en) 2008-10-08 2015-10-06 Trustees Of Dartmouth College Method for selectively inhibiting ACAT1 in the treatment of alzheimer's disease
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
CN101852805B (zh) * 2009-03-31 2015-04-01 浙江大学 Angptl3作为卵巢癌的诊断标记物的用途
AU2015200969A1 (en) * 2010-01-08 2015-03-19 Ionis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
CA2786071C (en) 2010-01-08 2021-01-12 Isis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
GEP201706660B (en) * 2010-03-04 2017-04-25 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
CA2826563C (en) 2011-02-07 2020-10-20 Paul Kussie Methods and systems for treating eclampsia and pre-eclampsia
US8852592B2 (en) 2011-05-10 2014-10-07 Biocare Medical, Llc Systems and methods for anti-PAX8 antibodies
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
EP3444348A1 (en) * 2011-06-21 2019-02-20 Alnylam Pharmaceuticals, Inc. Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
IL250396B (en) 2011-06-23 2022-06-01 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2756004B1 (en) 2011-09-16 2019-12-25 Regeneron Pharmaceuticals, Inc. INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9) FOR USE IN REDUCING LIPOPROTEIN(a) LEVELS
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
RS57704B1 (sr) 2012-07-13 2018-12-31 Roche Glycart Ag Bispecifična anti-vegf/anti-ang-2 antitela i njihova primena u lečenju vaskularnih bolesti oka
TWI596115B (zh) 2012-08-13 2017-08-21 再生元醫藥公司 具有ｐＨ－依賴性結合特性之抗－ＰＣＳＫ９抗體
EP2900265B1 (en) 2012-09-27 2018-05-30 Biocare Medical, LLC Anti-uroplakin ii antibodies systems and methods
GB201219487D0 (en) * 2012-10-30 2012-12-12 Cancer Rec Tech Ltd Anti-S100A4 antibody molecules and their uses
US10429390B2 (en) 2012-12-18 2019-10-01 Biocare Medical, Llc Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
JP6445467B2 (ja) 2013-02-28 2019-01-09 バイオケア メディカル， エルエルシー 抗ｐ４０抗体システムおよび方法
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
UY35368A (es) 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular
HUE050394T2 (hu) 2013-05-01 2020-11-30 Ionis Pharmaceuticals Inc Apolipoprotein(a) expressziójának módosítására szolgáló eljárások és készítmények
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
ES2765423T3 (es) 2013-10-03 2020-06-09 Biocare Medical Llc Sistemas y procedimientos de anticuerpos anti-SOX10
BR112016013514B1 (pt) 2013-12-13 2022-04-19 Stora Enso Oyj (Fi) Papelão de múltiplas camadas
US20170037409A1 (en) * 2013-12-24 2017-02-09 Ionis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
AU2015252895B2 (en) 2014-05-01 2021-07-15 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating angiopoietin-like 3 expression
WO2015184105A1 (en) 2014-05-29 2015-12-03 Trustees Of Dartmouth College Method for selectively inhibiting acat1 in the treatment of neurodegenerative diseases
US9527922B2 (en) * 2014-12-31 2016-12-27 Development Center For Biotechnology Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy
JP6975641B2 (ja) 2015-04-13 2021-12-01 アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. アンギオポエチン様３（ＡＮＧＰＴＬ３）ｉＲＮＡ組成物およびそれらの使用方法
EP3370708A4 (en) 2015-11-06 2019-06-26 Ionis Pharmaceuticals, Inc. MODULATION OF APOLIPOPROTEIN (A) EXPRESSION
IL260931B2 (en) * 2016-02-17 2024-09-01 Regeneron Pharma Methods of treating or preventing atherosclerosis by blocking ANGPTL3
WO2017151783A1 (en) 2016-03-03 2017-09-08 Regeneron Pharmaceuticals, Inc. Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor
MY198114A (en) 2016-04-15 2023-08-04 Macrogenics Inc Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
AU2017258105B2 (en) * 2016-04-28 2024-09-05 Regeneron Pharmaceuticals, Inc. Methods for treating patients with familial hypercholesterolemia
AU2017350947B2 (en) * 2016-10-28 2024-02-15 Washington University Anti-ApoE antibodies
CN107085112B (zh) * 2017-05-10 2019-03-19 武汉圣润生物科技有限公司 一种用于检测白血病的试剂盒
CN112334485B (zh) * 2018-04-06 2024-09-27 百进生物科技公司 抗-四次穿膜蛋白33药剂及其组合物以及制备和使用方法
MX2021001281A (es) 2018-08-02 2021-07-15 Dyne Therapeutics Inc Complejos dirigidos a músculos y sus usos para el tratamiento de distrofinopatías.
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
TWI747098B (zh) * 2018-12-21 2021-11-21 美商美國禮來大藥廠 抗angptl3/8複合物抗體及其使用方法
US20200369760A1 (en) 2019-05-24 2020-11-26 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-angptl3 antibodies
CN112062845B (zh) * 2019-06-10 2022-09-02 山东博安生物技术股份有限公司 Angptl3结合片段及其用途
EP3993820A4 (en) * 2019-07-04 2023-08-16 Cadila Healthcare Limited VACCINE BASED ON ANGPTL3 FOR THE TREATMENT OF LIVER DISEASES
WO2021041300A2 (en) * 2019-08-23 2021-03-04 Ab Therapeutics, Inc. Bispecific antibodies and uses thereof
CN110938144B (zh) * 2019-11-27 2022-07-26 复旦大学附属儿科医院 一种抗angptl3单克隆抗体及其在制备治疗肾病综合征药物中的用途
CN114829395B (zh) * 2020-01-22 2023-12-12 江苏恒瑞医药股份有限公司 抗angptl3抗体及其应用
WO2022109443A1 (en) * 2020-11-23 2022-05-27 The Regents Of The University Of Michigan Single-chain antibody against flavivirus ns1 protein
AU2022231003A1 (en) 2021-03-04 2023-09-14 Alnylam Pharmaceuticals, Inc. Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
WO2022187353A1 (en) * 2021-03-05 2022-09-09 Anji Pharmaceuticals Inc. Methods and compositions for treating sepsis
JPWO2022244845A1 (cg-RX-API-DMAC7.html) * 2021-05-19 2022-11-24
JP2024525608A (ja) 2021-07-09 2024-07-12 ダイン セラピューティクス，インコーポレーテッド ジストロフィン異常症を処置するための筋標的化複合体および製剤
AU2022307086A1 (en) * 2021-07-09 2024-01-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2023283624A2 (en) * 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
TW202320847A (zh) * 2021-07-21 2023-06-01 大陸商江蘇恆瑞醫藥股份有限公司 一種抗ａｎｇｐｔｌ３抗體或其抗原結合片段的醫藥組成物及其用途
CN116284377A (zh) * 2021-12-21 2023-06-23 复旦大学 抗人血管生成素3纳米抗体及其应用
AR129198A1 (es) 2022-05-02 2024-07-31 Novo Nordisk As Nuevos anticuerpos anti-angptl3 adecuados para composiciones de concentración alta
CN117447595B (zh) * 2022-07-26 2024-06-28 北京东方百泰生物科技股份有限公司 一种抗Siglec-15单克隆抗体
CN116199779B (zh) * 2022-12-08 2023-08-11 北京东方百泰生物科技股份有限公司 一种抗lilrb4单克隆抗体、其抗原结合片段及其应用
WO2024130165A1 (en) 2022-12-16 2024-06-20 Regeneron Pharmaceuticals, Inc. Angptl3 inhibitors for triglyceride reduction in multifactorial chylomicronemia syndrome
CN119192369A (zh) * 2023-06-25 2024-12-27 百奥泰生物制药股份有限公司 抗angptl3抗体及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
SG89295A1 (en) 1991-03-15 2002-06-18 Amgen Inc Pegylation of polypeptides
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
CA2103887C (en) 1991-12-13 2005-08-30 Gary M. Studnicka Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5912000A (en) 1994-09-23 1999-06-15 Zonagen, Inc. Chitosan induced immunopotentiation
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW313568B (cg-RX-API-DMAC7.html) 1994-12-20 1997-08-21 Hoffmann La Roche
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US20030100051A1 (en) 1998-05-12 2003-05-29 Ruben Steven M. 97 human secreted proteins
US5980912A (en) 1997-03-25 1999-11-09 Zonagen, Inc. Chitosan induced immunopotentiation
US6030831A (en) 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
AU4643699A (en) * 1998-06-24 2000-01-10 Compugen Ltd. Angiopoietin-like growth factor sequences
EP1239050A4 (en) 1999-12-09 2004-07-21 Sankyo Co METHOD FOR TESTING CURATIVE OR PREVENTIVE AGENT OF HYPERLIPEMIA
EP1403367A4 (en) 2001-06-08 2005-08-17 Sankyo Co A MEDICAMENT TEST METHOD FOR TREATING OR PREVENTING DISEASES SUCH AS HYPERLIPEMIA
EP1451578B1 (en) 2001-11-16 2013-08-21 Genentech, Inc. Use of angptl3 antagonists for the treatment of liver diseases
KR101387781B1 (ko) 2005-01-07 2014-04-21 렉시컨 파마슈티컬스 인코퍼레이티드 앤지오포이에틴-유사 단백질 4 (ａｎｇｐｔｌ４) 에 대한단일클론 항체
KR101503937B1 (ko) * 2006-12-08 2015-03-18 렉시컨 파마슈티컬스 인코퍼레이티드 Ａｎｇｐｔｌ３ 에 대한 단일클론 항체

Also Published As

Publication number Publication date
AU2007332855A1 (en) 2008-06-19
PT2121751T (pt) 2017-04-18
DK2121751T3 (en) 2017-04-24
CN101855241B (zh) 2013-11-06
US20080177045A1 (en) 2008-07-24
JP2010512320A (ja) 2010-04-22
AU2007332855B2 (en) 2012-08-16
BRPI0720218A2 (pt) 2013-12-24
WO2008073300A2 (en) 2008-06-19
KR101503937B1 (ko) 2015-03-18
EP2121751B1 (en) 2017-01-25
WO2008073300A3 (en) 2009-12-23
ES2618830T3 (es) 2017-06-22
US7935796B2 (en) 2011-05-03
EA019661B1 (ru) 2014-05-30
NO20092215L (no) 2009-08-19
KR20090088925A (ko) 2009-08-20
IL199216A (en) 2016-02-29
ZA200904022B (en) 2010-08-25
CA2672049C (en) 2016-05-10
EP2121751A2 (en) 2009-11-25
JP5484063B2 (ja) 2014-05-07
US8742075B2 (en) 2014-06-03
US20110243948A1 (en) 2011-10-06
EA200970556A1 (ru) 2010-04-30
AR064205A1 (es) 2009-03-18
TW200846364A (en) 2008-12-01
CN101855241A (zh) 2010-10-06
CA2672049A1 (en) 2008-06-19
EP2121751A4 (en) 2012-01-11
MX2009006082A (es) 2009-08-18
HUE033960T2 (en) 2018-01-29

Similar Documents

Publication Publication Date Title
ZA200904022B (en) Monoclonal antibodies against ANGPTL3
IL301499B2 (en) Glycosylated antibodies
IL194995A0 (en) Modified humanised anti-interleukin-18 antibodies
EP2021373A4 (en) MONOCLONAL ANTIBODY VCAM-1 SPECIFIC
HRP20181616T1 (hr) Potpuno ljudska anti-vap-1 monoklonska antitijela
SG10201404801YA (en) Monoclonal antibody
IL200168A0 (en) Monoclonal anti-cxcl13 antibodies
IL196806A0 (en) Anti-myostatin antibodies
IL204835A0 (en) Humanized antibody
SG10201601279SA (en) Monoclonal Antibody STRO-4
IL194776A0 (en) Humanized c-kit antibody
EP2331579A4 (en) MONOCLONAL ANTIBODIES
IL206710A0 (en) Il-31 monoclonal antibodies
EP2138576A4 (en) ANTI-CLAUDIN-4 ANTIBODY
SI2146745T1 (sl) Penta-specifično protitelo
IL193871A0 (en) Humanized anti-cd20 monoclonal antibody
PL2011869T3 (pl) Nowe przeciwciało anty-CD98
GB0615662D0 (en) Antibody
IL205073A0 (en) Anti-bst2 antibody
ZA200808647B (en) Glycosylated antibodies
EP2015785A4 (en) ANTIGEN AGRM2
ZA200901481B (en) Smallpox monoclonal antibody
HK1139157A (en) Monoclonal antibodies against angptl3
GB0606276D0 (en) Antibodies
GB0607376D0 (en) Antibodies